'On standalone basis

Quarter ended June 2025 compared with Quarter ended June 2024.

Net sales (including other operating income) of Pfizer has increased 7.14% to Rs 603.05 crore.  Operating profit margin has jumped from 31.53% to 34.83%, leading to 18.33% rise in operating profit to Rs 210.02 crore.  Raw material cost as a % of total sales (net of stock adjustments) increased from 9.50% to 14.66%.   Purchase of finished goods cost fell from 30.88% to 20.55%.   Employee cost increased from 15.04% to 15.84%.   Other expenses fell from 15.36% to 14.22%.   

Other income up 60.54% to Rs 67.17 crore.  PBIDT rose 26.38% to Rs 277.19 crore.  Provision for interest up 54.03% to Rs 3.25 crore.  

PBDT rose 26.11% to Rs 273.94 crore.  Provision for depreciation down 1.30% to Rs 14.41 crore.  

Profit before tax grew 28.09% to Rs 259.53 crore.&nbs...

• 

  (13-Jan-2026)

  HCL Technologies

  Revenue up 13.3% YoY to Rs 33872 crore in Q3FY2026
• 

  (13-Jan-2026)

  Tata Consultancy Services

  Revenue up 4.9% YoY to Rs 67087 crore in Q3FY2026
• 

  (12-Jan-2026)

  Krishana Phoschem

  Revenue up 116.8% YoY to Rs 659 crore in Q3FY2026
• 

  (11-Jan-2026)

  Avenue Supermarts

  Revenue up 13.3% YoY to Rs 18100.9 crore, Net profit up 18.3% yoy to Rs 855.9 crore in Q3FY2026